Expression and Immunogenicity Analysis of p53 Protein Fused with a New Cell-Penetrating Peptide

Bo ZHAO,Ting LIU,Mei SUN,Li-jin LAI,Ai-ling FU,Xing-ran XU

DOI: https://doi.org/10.13718/j.cnki.xdzk.2015.02.008

2015-01-01

Abstract:Objective:To express p53 protein fused with RDP ,a new cell‐penetrating peptide ,by the pro‐karyotic expression system and determine the strength of its immunogenicity .Methods :The coding se‐quence of p53 was amplified by PCR using plasmid pET28a‐p53 as a template and cloned into the prokary‐otic expression vector pET28a‐RDP .The constructed recombinant plasmid pET28a‐RDP‐p53 was trans‐formed into E. coli Rosetta ,protein expression was induced with IPTG and the protein was purified .The expressed product was identified by SDS‐PAGE .Then Kunming mice were divided into 4 groups ,i. e. blank control group (constant volume of normal saline) and RDP‐p53 fusion protein high‐dose ,medium‐dose and low‐dose groups (4 mg/kg ,2 mg/kg and 1 mg/kg) and were immunized by peritoneal ,once 2 d , of which the sera were separated 30 d later and determined for IgG level by ELISA .Results :Both restric‐tion analysis and sequencing proved that p53 gene was successfully cloned into the expression vector pET28a‐RDP ;RDP‐p53 fusion protein was expressed in both supernatant and precipitation .ELISA results showed that compared with the control group ,IgG content of the low‐dose and medium‐dose groups didn't increase significantly (p>0.05) ,but that of the high‐dose group increased significantly (p<0.05) .Con‐clusion:RDP‐p53 fusion protein was successfully expressed and purified ,it had weak immunogenicity and the immunogenicity was related to the dosage of administration ,which might provide some valuable infor‐mation for the study of the pharmacological effect of RDP‐p53 fusion protein for inhibiting brain tumors .